Earnings ·
Black Diamond Therapeutics reported financial results for the second quarter ended June 30, 2026
BDTXBlack Diamond Therapeutics, Inc.
Black Diamond Therapeutics reported financial results for the second quarter ended June 30, 2026. The company held $110.5 million in cash and investments as of June 30, sufficient to fund operations into late 2028. Net loss was $9.9 million, with R&D expenses at $7.4 million and G&A expenses at $4.7 million. Clinically, the company presented positive Phase 2 data for silevertinib in frontline non-classical EGFR-mutant NSCLC patients at ASCO, showing a CNS objective response rate of 86% and preliminary median progression-free survival of 15.2 months. The firm plans to provide an update on pivotal development path discussions with the FDA in Q4 2026. Black Diamond Therapeutics is a clinical-stage oncology company developing targeted cancer therapies.